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Abstract
Background: Mutations in the chromodomain helicase DNA binding protein 7 gene (CHD7) lead to CHARGE syndrome, an
autosomal dominant multiple malformation disorder. Proteins involved in chromatin remodeling typically act in
multiprotein complexes. We previously demonstrated that a part of human CHD7 interacts with a part of human CHD8,
another chromodomain helicase DNA binding protein presumably being involved in the pathogenesis of neurodevelop-
mental (NDD) and autism spectrum disorders (ASD). Because identification of novel CHD7 and CHD8 interacting partners
will provide further insights into the pathogenesis of CHARGE syndrome and ASD/NDD, we searched for additional
associated polypeptides using the method of stable isotope labeling by amino acids in cell culture (SILAC) in combination
with mass spectrometry.
Principle findings: The hitherto uncharacterized FAM124B (Family with sequence similarity 124B) was identified as a
potential interaction partner of both CHD7 and CHD8. We confirmed the result by co-immunoprecipitation studies and
showed a direct binding to the CHD8 part by direct yeast two hybrid experiments. Furthermore, we characterized FAM124B
as a mainly nuclear localized protein with a widespread expression in embryonic and adult mouse tissues.
Conclusion: Our results demonstrate that FAM124B is a potential interacting partner of a CHD7 and CHD8 containing
complex. From the overlapping expression pattern between Chd7 and Fam124B at murine embryonic day E12.5 and the
high expression of Fam124B in the developing mouse brain, we conclude that Fam124B is a novel protein possibly involved
in the pathogenesis of CHARGE syndrome and neurodevelopmental disorders.
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Introduction
In humans, CHD7 (NM _017780) is one of nine members of the
chromodomain helicase DNA binding domain (CHD) family that
plays a role in controlling gene expression by ATP-dependent
chromatin remodeling. Mutations in the CHD7 gene are the major
cause of CHARGE syndrome (OMIM 214800), an autosomal
dominant congenital malformation disorder characterized by the
combination of eye, ear, craniofacial structure, and heart defects
[1–6]. However, in 5–10% of patients with a typical presentation
of CHARGE syndrome and in 40–60% of patients with an
atypical presentation the underlying cause of the symptoms
remains unclear [7]. For other autosomal dominant disorders,
e.g. Noonan syndrome, a genetic heterogeneity is known, wherein
mutations in different genes lead to a similar phenotype.
Therefore, we hypothesize that in CHARGE syndrome, besides
mutations in CHD7, mutations in one or more additional and
hitherto unknown genes are involved in the pathogenesis of this
disease.
Proteins involved in chromatin remodeling are typically found
in multiprotein complexes. In recent and earlier studies different
CHD7 interacting partners have been described [8–13]. In human
neural crest-like cells CHD7 was shown to be associated with
components of the BAF- (Brahma associated factor complex) and
PBAF - complexes (Polybromo containing complex) [10]. Both
belong to the SWI/SNF-family of ATP-dependent chromatin
remodeling complexes and can act as transcriptional activators or
repressors [14]. In murine embryonic stem (ES) cells co-
localization between Chd7 and the proteins p300, Oct4, Sox2,
Nanog, Smad1 and Stat3 at enhancer elements was shown [12]
leading to the hypothesis that these proteins are cofactors in
enhancer promoter interactions [12]. CHD7 was also found to be
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pathogenesis of Treacher Collins syndrome [13]. These studies
demonstrate that there are numerous CHD7 interacting partners,
leading to the suggestion that there are cell type specific
compositions of CHD7 containing complexes and that the
subunits may change during development [7].
Recently, we demonstrated that a part of the human CHD7
protein interacts with a part of the CHD8 protein, another CHD
family member. Studies in Drosophila melanogaster demonstrated that
kismet is the only gene related to the human subgroup III members
(CHD6-CHD9). Kismet has a functional role in transcriptional
regulation by promoting early elongation by RNA Polymerase II
as well as by recruiting the histone methyltransferases ASH1 and
TRX to chromatin [15]. Rodriguez-Paredes et al. suggested that
in mammals the function of kismet is overtaken by several subgroup
III members (CHD6-CHD9) [16] and we hypothesized that
CHD7 and CHD8 build a core component of a complex with
similar functions such as kismet [11]. CHD8 was found to be
associated with the WAR complex [17]. This complex includes
WDR5, ASH2L and RbBP5 (WAR) and is known as a
subcomplex of mixed lineage leukemia (MLL) complexes, the
Drosophila homolog to TRX complexes. The MLL complexes act
as histone H3 Lys-4 methyltransferases [18].
Furthermore, CHD8 directly binds beta-catenin and negatively
regulates beta-catenin-targeted gene expression [17]. Microdele-
tions, chromosomal rearrangements disrupting CHD8 as well as de
novo missense and nonsense mutations in the CHD8 gene were
described in autism spectrum (ASD) and in neurodevelopmental
(NDD) disorder patients, indicating that alterations in CHD8 can
contribute to ASD and NDD [19–22].
Identification of novel CHD7 and CHD8 interacting partners
will provide further insights into the pathogenesis of CHARGE
syndrome and ASD/NDD. Therefore, we tried to detect new
binding partners by using the method of stable isotope labeling by
amino acids in cell culture (SILAC) in combination with mass
spectrometry. We identified FAM124B (Family with sequence
similarity 124B) as a potential interaction partner of both CHD7
and CHD8. Additionally, we confirmed the interaction by co-
immunoprecipitation and performed direct yeast two hybrid
experiments. Furthermore, we examined the intracellular locali-
zation and tissue specific expression of Fam124B during mouse
embryogenesis and in adult mouse tissues.
Results
Identification of FAM124B as Part of the CHD7 and CHD8
Interactomes
In order to identify novel CHD7 and CHD8 interaction
partners we applied stable isotope labeling by amino acids in cell
culture (SILAC) in combination with mass spectrometry [23,24]
(Figure 1). To achieve differential isotope labeling of HeLa cells,
one cell batch was cultured in the presence of lysine and arginine
containing light (L) isotopes of carbon and nitrogen (
12C and
14N,
L-lysine and L-arginine) while the other batch was cultured in the
presence of lysine and arginine containing heavy (H) isotopes of
carbon and nitrogen (
13C6
15N2-lysine and
13C6
15N4-arginine).
Accordingly, the two culture conditions confer distinct molecular
masses on the cellular proteins and in this way proteins derived
from SILAC-labeled cells can be distinguished and thus attributed
to the L- or H-labeled cell batch by mass spectrometry. For
elucidation of the CHD7- or CHD8 interactomes, the H-labeled
cells were firstly co-transfected with the plasmids CHD7-CR1-3-
pCMV-HA (containing amino acids 1593-2178, NP_060250.2, in
fusion with an HA-tag) and CHD8-pCMV-cmyc (spanning amino
acids 1789–2302, NP_065971.2, in fusion with an cmyc-tag). 24
hours post transfection, expression of the tagged proteins was
confirmed by western blotting. Subsequently, the respective H-
labeled cells were lysed and the CHD7 part was purified by anti-
HA immunoprecipitation. As a negative control the same
immunoprecipitation was performed in lysates of non-transfected
L-labeled HeLa cells. The purified proteins from both the H- and
L-states were then pooled in equimolar amounts and subsequently
digested with the endoproteinase trypsin. Derived peptides were
identified by liquid-chromatography (LC)-coupled tandem mass
spectrometry (MS/MS), allocated to the corresponding proteins by
database search and finally quantified using the MaxQuant
software. An at least five-fold enrichment of heavy versus light
peptides was considered to mark proteins that were specifically co-
purified with the HA-tagged CHD7 part. The same experimental
workflow was also performed with inverse labeling. In at least
three biological replicates FAM124B was co-purified with CHD7
and CHD8, identifying this so far uncharacterized protein as a
novel effector of the CHD7/8 interactome (Table S1–S3).
Full Length Cloning and Transcript Analysis of FAM124B
Information of the genomic and cDNA structure of FAM124B
was obtained from NCBI database. In humans, two transcript
variants are described. Transcript variant 1 contains two exons
with the ATG in exon one and the stop codon in exon 2 resulting
in a protein with 455 amino acids (NP_001116251.1). Transcript
variant 2 contains an alternate exon with an in-frame stop codon
leading to a shorter protein product with 272 amino acids
(NP_079061.2) (Figure 2). In mice, one transcript homologe to the
human transcript variant 1 containing 456 amino acids was
described (NP_775601.1). We validated the information by full
length cloning and sequencing of human and mouse cDNAs
derived from HeLa cells and mouse adult brain tissue, respectively.
Figure 1. Schematic overview of the SILAC approach. ‘‘Heavy’’-
labeled cells were co-transfected with the plasmids CHD7-CR1-3-pCMV-
HA (containing amino acids 1593-2178, NP_060250.2, in fusion with an
HA-tag) and CHD8-pCMV-cmyc (spanning amino acids 1789–2302,
NP_065971.2, in fusion with a cmyc-tag). The CHD7 part was purified by
anti-HA immunoprecipitation. As a negative control, the same
immunoprecipitation was performed in lysates of non-transfected
‘‘Light’’-labeled HeLa cells. Purified proteins from both cell cultures were
pooled in equimolar amounts and in-gel digested, followed by liquid-
chromatography (LC)-coupled tandem mass spectrometry.
doi:10.1371/journal.pone.0052640.g001
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and a Part of CHD8
Co-Immunoprecipitation studies on HeLa cells were performed
to confirm the CHD7-CHD8- FAM124B interaction. HeLa cells
were co-transfected with either the CHD7-CR1-3-pCMV-HA
(amino acids 1593-2178, NP_060250.2) plasmid and FAM124B-
1,3-pCMV-cmyc (transcript variant 1, NP_001116251.1) or with
CHD8-pCMV-cmyc (amino acids 1789-2302, NP_065971.2) and
FAM124B-1,3-pCMV-HA (transcript variant 1,
NP_001116251.1) (Figure 2). Total protein was isolated after 24
hours. Immunoprecipitation with either the anti-CHD7 (abcam,
ab31824) or the anti-CHD8 antibody (abcam, ab84527) and
detection with either the anti-cmyc (abcam, ab9106) or anti-HA
antibody (Roche) lead to an approximately 51 kDa band
corresponding to the estimated size of FAM124B transcript
variant 1 (Figure 3A). Reciprocal immunoprecipitation with anti-
cmyc antibody and detection with the anti-CHD7 antibody
demonstrated a specific band of ,70 kDa, the estimated size for
the CHD7 part fused to the HA-tag (Figure 3B). Using the anti-
HA-antibody for precipitation, we detected a ,68 kDa band
corresponding to the estimated size of the CHD8 part fused to the
cmyc tag (Figure 3C) by using the anti-CHD8 antibody.
The same experimental procedure was then performed with the
plasmid FAM124B-1,2-pCMV-HA (transcript variant 2,
NP_079061.2). Similar to the results for the FAM124B transcript
variant 1, we demonstrated an interaction with the CHD7 and
CHD8 part with FAM124B transcript variant 2 (Figure 3D–F).
FAM124B Interacts Directly with a Part of CHD8
Y2H experiments were performed to determine a direct
interaction between CHD7, CHD8 and both variants of
FAM124B using the following plasmids: FAM124B-1,3-pGADT7
(full length transcript variant 1), FAM124B-1,2-pGADT7 (full
length transcript variant 2), CHD7-CR1-3-pGBKT7 (amino acids
1591-2181, NP_060250.2) and CHD8-pGBKT7 (amino acids
1789–2302, NP_065971.2) (Figure 2). The yeast two hybrid
experiments revealed that both transcripts of FAM124B directly
interact with the CHD8 part, while no direct interaction with the
CHD7 part, spanning the amino acids 1591-2181, could be
observed (Figure 4). Because FAM124B transcript variants 1 and 2
have exon 1 in common, we hypothesized that the FAM124B-
CHD8 interacting area is located within exon 1 of FAM124B.
Subcellular Localization of FAM124B in HeLa Cells
To determine the subcellular localization of endogenous
FAM124B in HeLa cells, we performed immunofluorescence
staining by using a rabbit anti-FAM124B antibody (ProteinTech).
Overexpressed FAM124B is localized mainly in the nucleus
(Figure 5B). To test the specificity of the polyclonal anti-FAM124B
antibody, we transiently transfected HeLa cells with the plasmid
FAM124B-1,3-pCMV-cmyc to overexpress cmyc epitope tagged
Figure 2. Schematic overview of FAM124B, CHD7 and CHD8 and the constructs used. In humans, there are two transcript variants of
FAM124B. Transcript variant 1 codes for a protein with 455 amino acids (NP_001116251.1), while transcript variant 2 leads to a shorter protein
product with 272 amino acids (NP_079061.2). Both variants have the first 244 amino acids in common. All used FAM124B variant 1 and 2 constructs
are full length constructs. Bioinformatic analysis of the amino acid sequence of FAM124B failed to identify any known functional domain, while CHD7
and CHD8 consist of two N-terminal chromodomains (Chromo), followed by a SWI2/SNF2-like ATPase/helicase domain (Helicase/ATPase), three
conserved regions (CR1-3), a SANT domain and two BRK domains. The black lines mark the regions cloned into the Yeast two hybrid (pGBKT7,
pGADT7) and Co-IP (pCMV-HA, pCMV-cmyc) vectors.
doi:10.1371/journal.pone.0052640.g002
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the rabbit anti-FAM124B antibody, the nuclear localization of the
overexpressed protein was indicated by an intense signal
(Figure 5B). Immunofluorescence staining of recombinant c-myc
tagged FAM124B on the same cells using the anti-c-Myc-antibody
(abcam, ab9106) confirmed these results (Figure 5C). Due to the
transient transfection not all cells overexpressed FAM124B. By
using the anti-FAM124B antibody a weaker signal in the cell
nuclei of the untransfected surrounding cells (Figure 5B) and the
untransfected cells (Figure 5F) could be observed, indicating a
possible endogenous FAM124B expression.
Western Blot Analysis of Overexpressed FAM124B
Additionally, we performed western blot analysis on the nuclear
cell fraction of untransfected HeLa cells (endogenous FAM124B)
and FAM124B-1,3-pCMV-cmyc overexpressed HeLa total cell
lysate (overexpression of c-myc epitope tagged FAM124B-1,3).
Immunoblotting of the nuclear cell fraction of untransfected HeLa
cells revealed a specific band of approximately 57 kDa. The
predicted size of human endogenous FAM124B-1,3 is approxi-
mately 51 kDa. We hypothesize that the observed band could be
endogenous FAM124B and suggested that the difference between
the predicted and the observed size is due to posttranslational
modifications of the endogenous FAM124B. Immunoblotting
performed on FAM124B-1,3-pCMV-cmyc overexpressed HeLa
total cell lysate using the anti-FAM124B antibody revealed a
prominent band of 51 kDa, the estimated size of the overexpressed
FAM124B variant 1 in fusion with a c-myc-tag and weaker the
above described 57 kDa band. Immunoblotting using the anti-c-
Myc antibody showed only the 51 kDa band, representing the
overexpressed FAM124B fusion protein (Figure 5A).
Tissue Specific Expression of Murine Fam124B
The expression pattern of murine Fam124B was studied by
semiquantitative reverse transcription polymerase chain reaction
(RT-PCR) on RNA of wild type CD1 mouse tissues and E9.5 and
E12.5 embryos (Figure 6A). The RT-PCR results were validated
by quantitative real-time PCR (qRT PCR) in 3 biological and 3
technical replicates (data not shown). Relative mRNA expression
levels were determined by using DCt values and were normalized
to the housekeeping genes Gapdh, Hprt and Sdna. Although
quantitative RT-PCR showed a high variability of the Fam124B
expression status in different animals, the semiquantitative RT-
PCR results could be confirmed, with highest expression rate in
lung and lowest in liver. Western blotting and immunohistochem-
ical staining (IHC) performed on adult mouse tissues confirmed
the semiquantitative and quantitative RT-PCR results (Figure 6B
and C). Furthermore, we evaluated the expression level of
Fam124B in sections of adult mouse brains. Immunohistochemical
examination demonstrated an expression of Fam124B in different
brain areas (Figure 7). Fam124B is highly expressed in the cortex,
the hippocampus subfields 1–3 (CA1-3), the dentate gyrus, the
caudate putamen, and the cerebellum. In situ hybridization (ISH)
of cortex and hippocampus sections with a full length Fam124B
RNA probe supported the results obtained by IHC (Figure 8).
To explore the expression pattern of Fam124B during mouse
development, we extended our IHC studies to sections of E12.5
mouse embryos, the time point when organogenesis takes place.
Similar to adult mouse tissues, Fam124B expression at E12.5 was
observed in different inner organs, with lowest expression in liver
tissue (Figure 9A–H). In the developing heart, high expression was
detected particularly in the endothelial cells of the atrium and
along the trabeculated endocardium of the ventricle, whereas no
expression was observed in blood cells (Figure 9D). At E12.5 when
the developing lung is not yet divided into lobes, Fam124B
expression was detected in the stroma cells and in the epithelial
cells of the segmental bronchi (Figure 9G). Furthermore, Fam124B
was expressed in the developing cochlea and the surrounding
tissue (Figure 9E) as well as in neural cells. The dorsal root ganglia
and the precartilage condensation zones in the neural arch showed
Fam124B expression, while Fam124B expression was significantly
reduced in the cartilage (Figure 9B). High Fam124B expression
Figure 3. Co-immunoprecipitation of FAM124B with a part of CHD7 and CHD8. HeLa cells were co-transfected with either the CHD7-CR1-3-
pCMV-HA (amino acids 1593-2178, NP_060250.2) plasmid and FAM124B-1,3-pCMV-cmyc or FAM124B-1,3-pCMV-HA (transcript variant 1,
NP_001116251.1) or with CHD8-pCMV-cmyc (amino acids 1789-2302, NP_065971.2) and FAM124B-1,3-pCMV-HA (transcript variant 1,
NP_001116251.1). (A) Using the anti-CHD8 (abcam, ab84527) or the anti-CHD7 (abcam, ab31824) antibody for precipitation, we detected with
the anti-HA antibody (Roche) an approximately 51 kDa band corresponding to the estimated size of FAM124B transcript variant 1. Lane 1: co-
transfected Co-IP, lane 2: untransfected HeLa cells as negative control. (B) Reciprocal immunoprecipitation with anti-cmyc antibody (precipitating
FAM124B transcript variant 1), and detection with the anti-CHD7 antibody lead to a specific band ,70 kDa, the estimated size for the CHD7 part
fused to the HA-tag. Lane 1: co-transfected Co-IP, lane 2: untransfected HeLa cells as negative control. (C) Reciprocal experiment with anti-HA
antibody (precipitating FAM124B transcript variant 1) and detection with the anti-CHD8 antibody detected a specific band ,68 kDa, the estimated
size for the CHD8 part fused to the cmyc-tag. Lane 1: co-transfected Co-IP, lane 2: untransfected HeLa cells as negative control. (D, E, F) The same
experimental procedure was performed for FAM124B transcript variant 2, demonstrating a specific interaction of FAM124B transcript variant 2 with
the CHD7 and CHD8 part as well. Lane 1: co-transfected Co-IP, lane 2: untransfected HeLa cells as negative control.
doi:10.1371/journal.pone.0052640.g003
Characterization of FAM124B
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e52640could be found in the spinal cord (Figure 9F) and in the developing
brain (Figure S1).
Discussion
Loss of function mutations in CHD7 lead to CHARGE
syndrome, a well known malformation syndrome affecting several
organs and sensory systems. CHD7 regulates the transcription of
tissue specific target genes through the mechanism of ATP-
dependent chromatin remodeling [9,12,13,7]. Chromatin remod-
eling proteins are typically found in large multiprotein complexes.
For CHD7, several tissue specific interacting partners are
described [8,10,12,13]. Thus, it can be suggested that there are
cell type and developmental stage specific compositions of CHD7
containing complexes. However, the precise complex composi-
tions for each tissue are still unknown. In an earlier study, we
demonstrated that a part of human CHD7 interacts with a part of
human CHD8 both directly and indirectly, via potential linker
proteins [11]. Loss of function mutations in CHD8 as well as de
novo missense mutations were described in autism spectrum (ASD)
and neurodevelopmental (NDD) disorder patients [19–22].
Interestingly, Betancur and colleagues described autism spectrum
disorders in about two thirds of children with CHARGE syndrome
[25], which supports our hypothesis of a CHD7-CHD8 containing
complex regulating the same cell type specific target genes.
The identification and characterization of associated factors of a
CHD7-CHD8 containing complex might play an important role
in understanding the pathophysiology of CHARGE syndrome and
ASD/NDD. Therefore, to further characterize this complex and
to identify additional associated polypeptides interacting with the
recently described human CHD7 and CHD8 part, we used the
method of stable isotope labeling by amino acids in cell culture
(SILAC) in combination with mass spectrometry. As a result of
three biological replicates we identified the hitherto uncharacter-
Figure 4. Yeast two hybrid assay. (A) Direct yeast two hybrid experiment with the constructs FAM124B-1,3-pGADT7 (full length transcript variant
1) and CHD7-CR1-3-pGBKT7 (amino acids 1591-2181, NP_060250.2) demonstrating no direct interaction between FAM124B transcript variant 1 and
the CHD7 part, while (B) Direct yeast two hybrid experiment with the constructs FAM124B-1,3-pGADT7 (full length transcript variant 1) and CHD8-
pGBKT7 (amino acids 1789–2302, NP_065971.2) shows a direct interaction. The same experiments were performed for FAM124B transcript variant 2.
(C) Direct yeast two hybrid experiment with the constructs FAM124B-1,2-pGADT7 (full length transcript variant 2) and CHD7-CR1-3-pGBKT7 (amino
acids 1591-2181, NP_060250.2). (D) Direct yeast two hybrid experiment with the constructs FAM124B-1,2-pGADT7 (full length transcript variant 2)
and CHD8-pGBKT7 (amino acids 1789–2302, NP_065971.2). FAM124B transcript variant 2 interacts directly with the CHD8 part, while no direct
interaction with the CHD7 part could be observed.
doi:10.1371/journal.pone.0052640.g004
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humans, two FAM124B transcript variants are present, while in
mice, only one transcript, homologous to the human transcript
variant 1, exists. The interaction of both human FAM124B
transcript variants with the CHD7 and CHD8 part was confirmed
by co-immunoprecipitation experiments. Direct yeast-two hybrid
studies were performed to specify the FAM124B - CHD7 - CHD8
interaction areas. Both transcripts of human FAM124B interact
directly with the CHD8 part containing the amino acids 1789–
2302 (NP_065971.2), while the FAM124B - CHD7 interaction is
an indirect interaction or the interacting area is outside of the used
CHD7 part spanning amino acids 1591-2181 (NP_060250.2). The
biological role of human FAM124B or its orthologs in P.troglodytes,
C.lupus, B.taurus, R.norvegicus, M.musculus, G.gallus, D.rerio is still
unknown. Bioinformatic analysis of the amino acid sequence failed
to identify any known functional domain. To gain further insight
into the biological role of FAM124B and its mouse ortholog, we
examined the subcellular localization and the expression pattern.
Immunofluorescence microscopy of overexpressed FAM124B
indicated that overexpressed FAM124B is localized in the nucleus.
Using the FAM124B antibody we could observe in untransfected
HeLa cells a nuclear, but weaker signal as well, possibly indicating
a lower expression of endogenous FAM124B. CHD8 is described
as a nuclear protein as well [26]. Concerning CHD7, a dual
localization in the nucleoplasm and in the nucleolus was observed
[13]. Therefore, the interaction between FAM124B, CHD8 and
CHD7 is supposed to take place in the nucleus.
We detected Fam124B expression in various adult mouse
tissues, with highest expression in lung and heart, followed by
kidney, brain and testis, whereas its expression was weakest in liver
Figure 5. Western blot and immunocytochemistry of endogenous and overexpressed FAM124B. (A) Western blot analysis on protein
isolated from untransfected HeLa cells (endogenous FAM124B) and HeLa cells overexpressing the FAM124B-1,3-cmyc-tag fusion protein. Lane 1:
Immunoblotting of the nuclear cell fraction of untransfected HeLa cells using the FAM124B antibody. The predicted size of human endogenous
FAM124B-1,3 is approximately 51 kDa. However, we observed a band of approximately 57 kDa (labeled by an asterisk). We hypothesize that this
band could be endogenous FAM124B and the larger size is possibly due to posttranslational modifications of the endogenous protein. Lane 2:
Immunoblotting of FAM124B-1,3-pCMV-cmyc overexpressed HeLa total cell lysate using the rabbit anti-FAM124B antibody revealed a prominent
band of 51 kDa, the calculated size of human full length FAM124B variant 1 in fusion with a c-myc-tag and the band observed in untransfected HeLa
cells. Lane 3: Immunoblotting of the same HeLa cell lysate as shown in lane 2 using anti-c-Myc shows the 51 kDa band corresponding to the
overexpressed FAM124B. Lane 4: Marker. Protein quality was controlled using mouse anti-HSC70 producing a 70 kDa band. (B) Immunofluorescence
staining using the rabbit anti-Fam124B antibody on HeLa cells transiently transfected with the plasmid FAM124B-1,3-pCMV-cmyc (FAM124B
transcript variant 1 fused to an c-myc-tag). Due to the transient transfection not all cells overexpressed FAM124B. Transfected cells show a bright red
signal in the nucleus demonstrating a nuclear distribution. The weaker signal in the cell nuclei of the untransfected surrounding cells could possibly
reflect an endogenous FAM124B expression, which we detected by RT-PCR and mass spectrometry. (C) Immunofluorescence staining using the anti-
c-Myc antibody on the same HeLa cells transiently transfected with the plasmid FAM124B-1,3-pCMV-cmyc showing a bright green signal in the
nucleus of the transfected cells. No signal could be observed in the surrounding untransfected cells. (D) Cell nuclei were stained with DAPI (blue). (E)
Overlay of B,C and D. (F) Immunofluorescence staining using the rabbit anti-Fam124B antibody on untransfected HeLa cells revealed a weak nuclear
signal as it was observed in the surrounding untransfected cells (see Figure 5B). (G) Immunofluorescence staining using the anti-c-Myc antibody on
untransfected cells reveals no signal, as expected. (H) Staining of cell nuclei with DAPI (I) overlay of F,G and H. B,C,D,E: Scale bar=40 mm. F,G,H,I: Scale
bar=30 mm.
doi:10.1371/journal.pone.0052640.g005
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In adult mouse brain sections, we demonstrated Fam124B
expression in several areas. Within the brain, high expression
levels were found in the cortex, granular and purkinje cell layer of
the cerebellum, thalamic nuclei, caudate putamen, and hippo-
campus.
CHD8 expression was previously noted in various adult mouse
tissues including heart, brain, spleen, lung, liver, skeletal muscle,
kidney and testis [26].
In adult mouse tissues, CHD7 expression was determined in the
retina, in the cornea, brain, skeletal muscle, heart, kidney, lung,
olfactory epithelium and olfactory bulb [1,27]. According to these
previously described data we observed an overlapping expression
pattern between CHD7, Chd8 and Fam124B in adult mouse
tissues. Due to the fact that CHARGE syndrome is a develop-
mental disorder and NDD/ASD are caused by abnormal brain
development, we extended our Fam124B expression studies to
embryonic tissues. The expression pattern of CHD7 during
development has been studied in embryos of different mammalian
species, before [28,2,5,29,27,30]. During mouse development,
Chd7 was found to be expressed at E12.5 in a wide range of head
tissues (several brain areas with highest expression in proximity to
the ventricles, in the choroid plexus, developing olfactory
epithelium, ganglia of the cranial nerves, otic and optic pits, and
the developing inner ear) and several regions of the body
(especially the dorsal root ganglia and lung epithelium, as well as
stomach epithelium, kidney and heart) [28–30]. Fam124B
expression at E12.5 was found in a variety of embryonic tissues
(e.g. several brain areas, spinal cord, dorsal root ganglia,
developing cochlea and surrounding tissues, lung, heart, and
kidney), as well. Similar to the results of adult mouse tissues,
Fam124B expression at E12.5 correlated in many embryonic
tissues with the Chd7 expression pattern, and therefore Fam124B
was found to be expressed in organs affected in CHARGE
syndrome.
It has already been shown that CHD7 binds to methylated
histone H3 lysine 4 (H3K4) at enhancer elements and modifies cell
type specific gene expression in a fine-tuning manner [9,12].
Schnetz and colleagues hypothesized that the binding of a CHD7
containing complex to enhancer elements may modulate the
expression rate of target genes through enhancer-promotor
interactions [9,12]. In mouse ES cells, a subset of Chd7 sites
colocalize with p300, Oct4, Sox2 and Nanog. The subset of Chd7
sites which are not co-occupied by these proteins can also enhance
transcription [12]. However, the associated factors of these Chd7
sites are still unknown. Possibly, the identified novel Fam124B
may serve as an associated factor involved in Chd7 enhancer-
mediated transcription. Furthermore, the high Fam124B expres-
sion in the developing mouse brain and in neuronal tissues at
embryonic day E12.5 might indicate a role of FAM124B together
with CHD8 in neurodevelopmental and autism spectrum disor-
ders.
In summary, we identified FAM124B as a binding partner of a
part of CHD7 and CHD8. We conclude that FAM124B is an
associated factor of a CHD7 and CHD8 containing complex.
Fam124B is widely expressed at mouse developmental stage E12.5
with an overlapping expression to Chd7 and high expression in the
developing mouse brain. Therefore, we assume a role for
FAM124B in the pathogenesis of CHARGE syndrome and
NDD/ASD. The results of our interaction studies, the subcellular
localization, and expression profile of FAM124B provide valuable
information and represent a starting point for further functional
investigations on FAM124B and its possible role in CHARGE
syndrome and NDD/ASD.
Figure 6. Expression pattern of murine Fam124B. (A) Expression pattern of murine Fam124B by semiquantitative reverse transcription
polymerase chain reaction (RT-PCR) on wild type CD1 mouse tissues and E9.5 and E12.5 embryos demonstrating expression in various tissues and
during development. (B) Western blot analysis of endogenous Fam124B on various mouse tissues using the anti-FAM124B antibody demonstrates
expression in heart, testis, kidney and highest in lung. A weak signal was detected in liver. (C) Immunohistochemistry (IHC) performed on adult
mouse tissues slightly counterstained with haematoxylin (blue) confirmed the semiquantitative RT-PCR and western blot results with high expression
(brown) in lung, heart, kidney, moderate expression in brain and testis, and very low expression in liver (most liver cell nuclei are only stained with
haematoxylin (blue)). Scale bar=20 mm. Negative=negative control was performed without using the primary antibody.
doi:10.1371/journal.pone.0052640.g006
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Ethics Statement/mouse Strains
The animal studies were approved by the Institutional Animal
Care and Use Committee of the University of Go ¨ttingen. All
mouse studies were performed on CD1 wildtype mice.
Stable Isotope Labeling by Amino Acids in Cell Culture
(SILAC) and Mass Spectrometry (MS)
Two HeLa cell populations were grown in SILAC DMEM
culture media (10% dialyzed FBS and 1% penstrep) (PAA
Laboratories GmbH, Pasching, Austria; Thermo Fisher Scientific,
Waltham, MA). The ‘‘light’’ SILAC medium was supplemented
with unlabeled L-lysine and L-arginine, while the ‘‘heavy’’ SILAC
medium was supplemented with arginine and lysine containing
heavy isotopes of carbon and nitrogen (
13C6-lysine and
13C6
15N4-
arginine). Upon metabolic labeling of the cells this leads to a mass
shift of +6 and +10 Da per incorporated arginine and lysine,
respectively. After at least 5 cell passages, co-transfection with the
previously described plasmids CHD7-CR1-3-pCMV-HA and
CHD8-pCMV-cmyc [11] into either L- or H-labeled HeLa cells
was performed. Non transfected L- or H-labeled cells were used as
negative control. After transient co-transfection, the cells were
incubated at 37uC for 24 hours, then washed with DPBS (PAN
BIOTECH GmbH, Aidenbach, Germany) and trypsinized
(Invitrogen, Carlsbad, CA, USA). To isolate the same amount of
protein from both cell cultures, cell populations were accurately
counted under microscope using counting chambers (Neubauer
haemocytometer) (approximately 1 - 1,26107 cells were used)
before cell lysis, which was performed as described by Oellerich
Figure 7. Fam124B expression in the mouse central nervous system. (A) Overview, (B) Thalamic nuclei, (C) Hippocampus, (D) Caudate
Putamen, (E) Cerebellum. CC=Corpus Callosum, Hipp=Hippocampus, CA1-3=Cornu Ammonis areas, DG=dentate gyrus, CP=Caudate Putamen,
adt=anterior dorsal thalamic nucleus, dg=granual layer of dentate gyrus, lv=lateral ventricle, F=fornix, mdt=mediodorsal thalamic nucleus,
IIIv=third ventricle with choroid plexus, vpl=ventral posterior thalamic nucleus, lateral part, ML=molecular layer of cerebellum, PL=purkinje cell
layer of cerebellum, GL=granular layer of cerebellum, Scale bar=100 mm.
doi:10.1371/journal.pone.0052640.g007
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monoclonal anti-Ha antibody (Roche Diagnostik GmbH, Mann-
heim, Germany) at 4uC overnight. Proteins coupled with the
antibody were incubated at 4uC with 100 ml of protein G
(Immunoprecipitation Kit, Roche Diagnostik GmbH, Mannheim,
Germany) for further 2 hours. Centrifugation at 350 rpm for
3 min was carried out to collect the agarose beads. To remove
unbound proteins, the beads were washed two times in 500 ml
lysis buffer and one time with 1 ml washing buffer 2 (Immuno-
precipitation Kit, Roche Diagnostik GmbH, Mannheim, Ger-
many). The beads were resuspended in 50 ml NuPAGE LDS
Sample buffer (Invitrogen, Carlsbad, CA, USA) supplemented
with 0.1 M DTT. After denaturation for 10 min at 95uC, the
denaturated H- and L-labeled proteins were pooled in equimolar
amounts and subsequently the samples were separated by size
using an 1D-PAGE (Invitrogen, Carlsbad, CA, USA) followed by
coomassie blue staining. Each gel lane was cut into 23 gel slices.
Proteins from each slice were in-gel digested with trypsin
(Promega, Madison, WI) according to the protocol described by
Shevchenko et al. (2006) [31]. MS measurements were carried out
using a nanoflow HPLC (Agilent, Boeblingen, Germany) coupled
to a nanoelectrospray LTQ-Orbitrap XL mass spectrometer
(Thermo Fisher Scientific, Waltham, MA) as described by Nikolov
et al. (2011) [32].
RNA Isolation and Semiquantitative Reverse-transcription
PCR
Total RNA was isolated from HeLa cells, MRC-CV1 cells or
different mouse tissues using Trizol reagent (Invitrogen, Carlsbad,
CA, USA). Homogenizing was carried out with Tissue lyser LT
(Qiagen GmbH, Hilden, Germany). 5 mg of total RNA from each
sample was reverse-transcribed using Superscript II reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). For each PCR
reaction 0.5 ml undiluted cDNA and 0.2 ml platinum taq
polymerase (Invitrogen, Carlsbad, CA, USA) was used. Human
cDNA isolated from HeLa and MRC-CV1 cells were amplified
using the following primers: 59-CCTTCTACA-
CACGCTGTCTTTG-39 as forward primer and 59-GGGGAT-
GAGCTATGCAACCTAAG-39 as reverse primer. RT-PCR on
mouse tissues was carried out using the following primer pair:
forward primer 59-GGTGGCCTTCATCATAATCTTC-39 and
reverse primer 59-CCAGTCACACTCTTGCT TCTGT-39. The
correct sequence was confirmed by sequence analysis.
Quantitative RT-PCR
Realtime PCR reactions were performed using 1 ml of 1:10
diluted cDNA from different CD1 mouse tissues, SYBR green
(Invitrogen, Carlsbad, CA, USA) and the gene-specific primers
forward 59-CCGTGTGTTCCCATCAGCAG-39 and reverse 59-
CTCCTCCTCCGGCTCCTTG-39. Relative mRNA expression
levels were determined using DCt values and were normalized to
the housekeeping genes Gapdh, Hprt and Sdna. The experiment was
performed in three biological and 3 technical replicates.
Co-immunoprecipitation
For co-immunoprecipitation studies we generated the plasmids
FAM124B-1,3-pCMV-HA (transcript variant 1,
NP_001116251.1), FAM124B-1,2-pCMV-HA (transcript variant
2, NP_079061.2), FAM124B-1,3-pCMV-cmyc (transcript variant
1, NP_001116251.1) and FAM124B-1,2-pCMV-cmyc (transcript
variant 2, NP_079061.2) by cloning the human full-length
sequence of transcript variant 1 and transcript variant 2 in frame
to the hemagglutinin (HA) epitope tag into the pCMV-HA vector
(Clontech, Mountain View, CA, USA) or in frame to the N-
terminal c-Myc epitope tag into the pCMV-Myc vector (Clontech,
Mountain View, CA, USA) by using the In Fusion Advantage Kit
(Clontech, Mountain View, CA, USA) according to the company’s
protocol. The correct reading frame and sequence were confirmed
by sequence analysis.
HeLa cells were cultured in 50 ml flasks (Sarstedt, Newton, NC,
USA) and were co-transfected with CHD7-CR1-3-pCMV-HA
(amino acids 1593-2178, NP_060250.2) and either FAM124B-1,3-
pCMV-cmyc or FAM124B-1,2-pCMV-cmyc. Additionally, we co-
transfected HeLa cells with CHD8-pCMV-cmyc (amino acids
Figure 8. In situ hybridization of Fam124B on mouse brain cryosections in comparison with immunostaining. (A) Immunostaining of a
cortex section, (B) In situ hybridization (ISH) of a cortex section (C) Sense control of ISH. (D) Immunostaining of a hippocampus section, (E) In situ
hybridization of a hippocampus section (F) Sense control of ISH. DG=dentate gyrus. Scale bar=100 mm.
doi:10.1371/journal.pone.0052640.g008
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or FAM124B-1,2-pCMV-HA. After 24 h of incubation at 37uC,
co-immunoprecipitations were carried out as previously described
[11]. For immunoblotting we used the following antibodies: anti-c-
Myc (abcam, ab9106) at a dilution of 1:2000, anti-HA (Roche
Diagnostik GmbH, Mannheim, Germany) at a dilution of 1:1000,
goat anti-CHD7 (abcam, ab 65097) at a dilution of 1:2000, rabbit
anti-CHD8 (abcam, ab84527) at a dilution of 1:2000. The
following antibodies were used for detection: goat anti-rabbit
IgG peroxidase secondary antibody (Sigma-aldrich, St.Louis, MO,
USA) for anti-c-Myc and anti-CHD8, goat anti-Rat secondary
antibody conjugated with horseradish peroxidase (Thermo Scien-
tific, Rockford, IL, USA) for anti-HA, donkey anti-goat IgG
peroxidase secondary antibody (Santa-Cruz Biotechnologies,
California, USA) for anti-CHD7.
Yeast Two Hybrid
For yeast two hybrid studies we generated the constructs
FAM124B-1,3-pGBKT7 (transcript variant 1, NP_001116251.1),
FAM124B-1,2-pGBKT7 (transcript variant 2, NP_079061.2),
FAM124B-1,3-pGADT7 (transcript variant 1, NP_001116251.1)
and FAM124B-1,2-pGADT7 (transcript variant 2, NP_079061.2).
The human full length sequence of transcript variant 1 and
transcript variant 2 were subcloned in frame to the ATG of the
pGBKT7 or pGADT7 vector (Clontech, Mountain View, CA) by
using the In Fusion Advantage Kit (Clontech, Mountain View,
CA). All constructs were transformed into Y2HGold strain cells
(Clontech, Mountain View, CA) and tested for toxicity and
autoactivation of the bait or prey reporter genes. No toxicity for
the yeast cells could be observed, but the FAM124B-1,3-pGBKT7
and FAM124B-1,2-pGBKT7 showed autoactivation. Therefore,
the further experiments were performed with the FAM124B-1,3-
pGADT7 and FAM124B-1,2-pGADT7 constructs. These both
plasmids were co-transformed into Y2HGold strain cells together
with either the CHD7-CR1-3-pGBKT7 (amino acids 1591-2181,
NP_060250.2) or the CHD8-pGBKT7 (amino acids 1789–2302,
NP_065971.2) plasmids. The direct Yeast two hybrid was
performed according to the manufactures’ protocol.
Cryosections
Adult brains from CD1 mice were isolated and fixed overnight
in 4% paraformaldehyde (PFA) solution prepared in sterile PBS
with DEPC water at 4uC with gentle shaking. On the next day, the
tissues were washed 3 times with sterile PBS/DEPC at 4uC and
Figure 9. Fam124B expression at murine embryonic stage E12.5 (sagittal sections). Fam124B expression (brown) was found in a variety of
embryonic tissues. Expression was observed in several brain areas, spinal cord, dorsal root ganglia, developing cochlea and surrounding tissues, lung,
heart, and kidney. Low expression was found in the developing liver and no expression (blue) in blood cells. (A) Overview of Fam124B
immunostaining on sagittal section of an E12.5 wildtype embryo slightly counterstained with haematoxylin, scale bar=200 mm. Higher magnification
of (B) Dorsal root ganglia, scale bar=100 mm( C) Nasal region, scale bar=100 mm( D) The developing heart, scale bar=100 mm( E) The developing
liver (L), scale bar=50 mm( F) spinal cord (sc), scale bar=50 mm( G) The developing lung with segmental bronchus (sb), scale bar=100 mm( H)
Cochlea, and surrounding tissue, scale bar=100 mm. LV=lateral ventricle, ch.p=choroid plexus differentiating from fourth ventricle, co=cochlea,
cd=cochlear duct, ne=nasal epithelium, V gan=left trigeminal (V) ganglion, drg=dorsal root ganglion, VIII gan=Vestibulocochlear (VIII) ganglion,
at=left atrium of heart, vt=left heart ventricle, ec=endothelial cells, car=cartilage primordium of body of vertebra, ccp=cartilage condensation
being primordium of vertebral body.
doi:10.1371/journal.pone.0052640.g009
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shaking till the tissues sank down. Then the brains were incubated
for 30 minutes to 1 hour at 4uC in a 1:1 mixture containing 30%
sucrose and Jung tissue freezing medium (Leica Microsystems,
Nussloch, Germany), following an incubation in tissue freezing
medium at 4uC for 30 minutes and embedded on dry ice in tissue
freezing medium. The frozen block was kept till usage at 280uC
and cut by cryo-microtome (Leica Instrument, Nussloch, Ger-
many) with 20 mm thickness and sticked on Menzel Superfrost
microscope slides (Thermo Scientific, Rockford, IL, USA).
In situ Hybridization
In situ hybridization was performed on cryosections of adult
brains from CD1 mice. The following primer pairs were used to
amplify by RT-PCR the whole coding region of Fam124B: forward
59- GCCATGGATGAGATACAGGAA-39 and reverse 59- CAT-
GAATGGGGCTGACTCTTA-39. The PCR product was sub-
cloned into the pGEMT easy vector (Promega, Madison, WI) and
transformed into E.coli. Positive plasmids were isolated and
sequenced. For probe amplification from a correct plasmid the
following primers were used for the Sp6 transcript: pGEM-T-Sp6-
F (ACGTCGCATGCTCCCG) and pGEM-T-R2
(CCAGGCTTTACACTTTATGCTTCC) and for the T7 tran-
script: PCR-T7 (CTGCGCAACTGTTGGG) and pGEM-T-R1
(AGGCGGCCGCGAATTCAC). The PCR products were gelex-
tracted and DIG-labelled RNA probes were synthesized using the
DIG RNA Labeling Kit (SP6/T7) (Roche Diagnostik GmbH,
Mannheim, Germany) according to the manufacturer’s protocol.
Synthesized probes were ethanol precipitated and resuspended in
100 ml of DEPC water/formamide 1:1 mixture and kept till usage
at 220uC. Non-radioactive in situ hybridization have been done
according to Moorman et al. (2001) [33]. The results have been
observed using a BX60 microscope (Olympus, Hamburg,
Germany) and images were processed by the analysis program
(CellSens Dimension, Olympus).
Immunocytochemistry on HeLa Cells
HeLa cells were transfected with the FAM124B-1,3-pCMV-
cmyc construct. Cell culture and staining procedure was carried
out as described previously [11]. As a blocking solution 10% sheep
serum diluted in DPBS with 0.1% Tween 20 (TPBS) was used.
Rabbit anti-FAM124B antibody (Proteintech Group, Chicago, IL)
was diluted at 1:50. As secondary antibody anti-rabbit IgG
conjugated with Cy3 (Sigma-Aldrich, St.Louis, MO, USA)
antibody and anti-mouse IgG conjugated with FITC (Sigma-
aldrich, St.Louis, MO, USA) antibody were used at a dilution of
1:400. Imaging was performed and processed using Olympus
Fluoview FV1000 microscope (Olympus, Hamburg, Germany)
and images were analyzed using the program FV10-ASW version
01.07.03.00.
Isolation of Protein and Immunoblotting
Total fractions of proteins were isolated from adult tissues of
CD1 mouse line using RIPA buffer (50 mM Tris-HCl pH 74, 1%
NP-40, 0.25% Sodium-deoxycholate buffer, 150 mM NaCl,
1 mM EDTA and protease inhibitors). Proteins were separated
by a 4–12% NuPAGE Bis-Tris gel (Invitrogen, Carlsbad, CA,
USA) and transferred to a nitrocellulose membrane (0.45 mm)
using a semi-dry system at 100 mA for 90 minutes. Membranes
were blocked with 5% BSA/TBST (PAA laboratories, Linz,
Austria) for Fam124B blotting while 5% milk/TBST (Carl Roth
GmbH, Karlsruhe) blocking buffer was used for all other blottings.
The blocked membranes were incubated with appropriate
primary antibodies overnight at 4uC. Rabbit anti-FAM124B
(Proteintech Group, Chicago, IL) was diluted at 1:200 in 1%
BSA/TBST, rabbit anti-c-Myc (abcam, ab9106) and mouse anti-
HSC70 (sc-7298, Santa Cruz Biotechnology, California, USA)
were diluted at 1:2000 and 1:10000 in 2% milk/TBST,
respectively. After washing, the membrane was incubated with
the following secondary antibodies: anti-rabbit IgG peroxidase
secondary antibody (Sigma-aldrich, St.Louis, MO, USA) for anti-
c-Myc and anti-Fam124B, anti-mouse IgG peroxidase secondary
antibody (Jackson ImmunoResearch Laboratories, Pennsylvania)
for anti-HSC70. The membrane was washed and super signal
West Pico chemiluminescent substrate (Thermo Scientific, Rock-
ford, IL, USA) was applied on the membrane and positive bands
were detected on a clear blue X-ray film (Thermo Scientific,
Rockford, IL, USA).
The nuclear fraction of untransfected HeLa cells and
FAM124B-1,3-pCMV-cmyc overexpressed HeLa total cell lysate
was immunoblotted using anti-FAM124B (Proteintech Group,
Chicago, IL) at a dilution of 1:200. FAM124B-1,3-pCMV-cmyc
overexpressed HeLa total cell lysate was immunoblotted addition-
ally with anti-c-Myc (abcam, ab9106) at a dilution of 1:2000.
Protein quality was controlled using mouse anti-HSC70 (sc-7298,
Santa Cruz Biotechnology, California, USA) at a dilution of
1:10000.
Immunohistochemistry on Paraffin Embedded Tissues
Adult wild type CD1 mouse tissues and E12.5 embryos were
paraffin embedded according to standard procedures. From the
paraffin embedded tissues 7 mm sections were made and incubated
overnight at 45uC. After a three time xylene incubation (10, 5, 5
minutes) a series of ethanol incubation (100%, 95%, 90%, 80%,
70%, 50%) and a washing step with DPBS for 2 minutes followed.
Slides were cooked with an antigen retrieval buffer (citric acid
0.1 M; EDTA 0.01%, pH 6.2) in a steam cooker for 10 minutes,
followed by a cool down step on ice for at least 10 minutes.
Endogenous peroxidase activity was blocked using 6% H2O2
solution in water for 15 minutes. The solution was tapped off from
the slides and blocked with horse serum (Vectastain Universal
Quick kit, Vector Laboratories, Burlingame, CA) for 30 minutes in
a humidity chamber at room temperature. Rabbit anti-FAM124B
(Protein Tech), rabbit anti-CHD7 (abcam, ab31824) and rabbit
anti-CHD8 (abcam, ab84527) antibodies were diluted at 1:50,
1:50 and 1:100, respectively. The primary antibodies were
incubated at 4uC overnight. After washing with TPBS for 5
minutes, a Pan specific secondary antibody (Vectastain Universal
Quick kit, Vector Laboratories, Burlingame, CA) was applied for
maximum 10 minutes and washed again with TPBS for 5 minutes.
Streptavidin peroxidase (Vectastain Universal Quick kit, Vector
Laboratories, Burlingame, CA) was applied on the slides for 5
minutes. Slides were then transferred to TPBS washing buffer for
minimum 5 minutes. The staining was developed with DAB
substrate (Roche Diagnostik GmbH, Mannheim, Germany) for
around 2 minutes. The slides were rinsed for minimum 5 minutes
under tap water and counterstained in mayor’s hematoxylin for
20–40 seconds and washed with tap water 3–4 times. Mounting of
slides were done with Aqua polymount (Polysciences Inc.,
Warrington, PA). Imaging was performed and processed using a
BX60 microscope (Olympus, Hamburg, Germany) and the
analySIS program Cell-Sens Dimension.
Supporting Information
Figure S1 Fam124B expression in the developing brain
at murine embryonic stage E12.5 (coronal sections). (A)
Overview of Fam124B immunostaining of the developing brain
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tion of the trigeminal ganglion, (C) Aqueduct of sylvius with
choroid plexus=AQ (D) Higher magnification of the medulla
(me) with spinal tract of trigeminal nerve (Vsp), nV=trigeminal
nucleus, MLF=medial longitudinal fasciculus (E) Higher magni-
fication of the eye, nr=neural retina, lf=lens fibers, vb=vitreous
body. Scale bar=50 mm.
(TIF)
Table S1 Proteins found by SILAC in combination with
mass spectrometry 1
st experiment (XLS).
(XLS)
Table S2 Proteins found by SILAC in combination with
mass spectrometry 2
nd experiment (XLS).
(XLS)
Table S3 Proteins found by SILAC in combination with
mass spectrometry 3
rd experiment (XLS).
(XLS)
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